Clinical Trial Update: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study evaluating gemcitabine with ex vivo expanded allogeneic universal donor NK cells, with or without Naxitamab (Danyelz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ex vivo Expanded Allogeneic Universal Donor NK Cells (TGFβi NK cells) (allogeneic universal donor NK cells with TGFβ inhibition)
• Gemcitabine (Gemcitabine)
• Naxitamab (naxitamab)

Snippet

Sponsor: Margaret Gatti-Mays | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma | Phase 1, Phase 2 | Status: RECRUITING